Skip to main content
. 2018 Dec 6;16:228. doi: 10.1186/s12916-018-1213-5

Fig. 2.

Fig. 2

Impact of the annual HZ/su waning rate starting 4 years following vaccination on the threshold vaccine cost per series when using a a time horizon of 15 years or b a lifetime time horizon. The cost-effectiveness threshold was set at €20,000 per quality-adjusted life year gained. HZ, herpes zoster; HZ/su, herpes zoster subunit vaccine; VE, vaccine efficacy